|
| | | | | | | | | | | |
| Brand | Indication | MOA | Approved | Economics | | | | Price | 127.02 | |
| Adcetris (brentuximab vedotin) | HL | | | TAK, BMS, U Miami | | | | Shares | 185.664901 | Q322 |
| Padcev (enfortumab vedotin) | mUC | | | 4503 | | | | MC | 23583.15572502 | |
| Tukysa (tucatinib) | mBC | | | | | | | Cash | 1763.7020000000002 | Q322 |
| Tivdak (tisotumab vedotin) | Cevical | | | | | | | Debt | 0 | Q322 |
| Blenrep | | | | GSK | | | | EV | 21819.453725019997 | |
| Polivy | | | | ROG | | | | | | |
| | | | Phase | | | | | CEO | | |
| telisotuzumab vedotin | | | II | ABBV | | | | CMO | Roger Dansey | |
| disitamab vedotin | mUC | | II | | | | | | | |
| ladiratuzumab vedotin | mTNBC | | II | | | | | | | |
| SEA-CD40 | | | II | | | | | | | |
| SEA-BCMA | | | I | | | | | Incorporated 7/15/1997 | | |
| SGN-CD228A | | | I | | | | | | | |
| LAVA-1223 | | | PC | | | | | | | |
| SEA-TGT | | | I | | | | | | | |
| SGN-B6A | | | I | | | | | | | |
| SGN-STNV | | | I | | | | | | | |
| SGN-B7H4V | | | I | | | | | | | |
| SGN-PDL1V | | | I | | | | | | | |
| SGN-ALPV | | | I | | | | | | | |
| SEA-CD70 | | | I | | | | | | | |